COSMOS HEALTH INC.

NASDAQ: COSM (Cosmos Health Inc.)

Last update: 10 Apr, 10:33PM

0.349

0.00 (0.66%)

Previous Close 0.347
Open 0.350
Volume 254,739
Avg. Volume (3M) 451,846
Market Cap 8,122,252
Price / Sales 0.130
Price / Book 0.400
52 Weeks Range
0.311 (-10%) — 1.58 (352%)
Earnings Date 14 Nov 2024
Profit Margin -29.73%
Operating Margin (TTM) -60.99%
Diluted EPS (TTM) -1.17
Quarterly Revenue Growth (YOY) -10.20%
Total Debt/Equity (MRQ) 48.18%
Current Ratio (MRQ) 0.990
Operating Cash Flow (TTM) -7.72 M
Levered Free Cash Flow (TTM) -1.94 M
Return on Assets (TTM) -15.85%
Return on Equity (TTM) -53.43%

Market Trend

Short Term Medium Term
Industry Medical Distribution (US) Bullish Bearish
Medical Distribution (Global) Mixed Bearish
Stock Cosmos Health Inc. - -

AIStockmoo Score

0.9
Analyst Consensus 2.0
Insider Activity NA
Price Volatility 0.5
Technical Moving Averages 3.5
Technical Oscillators -2.5
Average 0.88

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
COSM 8 M - - 0.400
PDCO 3 B 2.50% 20.38 2.80
EDAP 52 M - - 1.19
HSIC 8 B - 21.22 2.34
ZYXI 76 M - 28.00 1.85
AHG 464 M - - 2.27

Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.

Sector Healthcare
Industry Medical Distribution
Investment Style Small Value
% Held by Insiders 25.28%
% Held by Institutions 5.94%

No data within this time range.

No data within this time range.

Date Type Details
16 Apr 2025 Announcement Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
16 Apr 2025 Announcement Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
09 Apr 2025 Announcement Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L
09 Apr 2025 Announcement Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L
08 Apr 2025 Announcement Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order
08 Apr 2025 Announcement Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order
26 Feb 2025 Announcement Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates
18 Feb 2025 Announcement Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1
10 Feb 2025 Announcement Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations
07 Feb 2025 Announcement Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility
06 Feb 2025 Announcement Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria